{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Tumors&page=27",
    "query": {
      "condition": "Renal Tumors",
      "page": 27
    },
    "page_size": 10
  },
  "pagination": {
    "page": 27,
    "page_size": 10,
    "total_count": 1797,
    "total_pages": 180,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Tumors&page=28&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Renal+Tumors&page=26&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T04:56:58.652Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07297160",
      "title": "CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Myeloma",
        "Solid Tumors",
        "Sarcoma",
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "Dose Level -1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose Level 1 (starting dose level)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose Level 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Dose Level 3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "0 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2026-06",
      "completion_date": "2044-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-16T04:56:58.652Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07297160"
    },
    {
      "nct_id": "NCT05969496",
      "title": "Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Renal Cancer",
        "Kidney Cancer",
        "Renal Cell Carcinoma",
        "Inferior Vena Cava Thrombosis"
      ],
      "interventions": [
        {
          "name": "Axitinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2023-12-04",
      "completion_date": "2029-11",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-16T04:56:58.652Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Highlands Ranch, Colorado • Lone Tree, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Highlands Ranch",
          "state": "Colorado"
        },
        {
          "city": "Lone Tree",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05969496"
    },
    {
      "nct_id": "NCT03220035",
      "title": "Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma",
        "Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma",
        "Ependymoma",
        "Ewing Sarcoma",
        "Hepatoblastoma",
        "Langerhans Cell Histiocytosis",
        "Malignant Germ Cell Tumor",
        "Malignant Glioma",
        "Osteosarcoma",
        "Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Childhood Central Nervous System Neoplasm",
        "Recurrent Childhood Non-Hodgkin Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Neuroblastoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Primary Central Nervous System Neoplasm",
        "Rhabdoid Tumor",
        "Rhabdomyosarcoma",
        "Soft Tissue Sarcoma",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 4,
      "start_date": "2017-11-08",
      "completion_date": "2024-12-31",
      "has_results": true,
      "last_update_posted_date": "2025-01-27",
      "last_synced_at": "2026-10-16T04:56:58.652Z",
      "location_count": 114,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 90 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03220035"
    },
    {
      "nct_id": "NCT05871008",
      "title": "Integrated Actionable Aging Assessment for Cancer Patients Pilot",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Hodgkin Lymphoma",
        "Kidney Cancer",
        "Leukemia",
        "Lymphoid Leukemia",
        "Multiple Myeloma",
        "Myeloid Leukemia",
        "Monocytic Leukemia",
        "Prostate Cancer",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Assessment tool IA3-CP with SDoH",
          "type": "OTHER"
        },
        {
          "name": "Assessment tool IA3-CP without SDoH",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "111 Years",
        "sex": "ALL",
        "summary": "65 Years to 111 Years"
      },
      "enrollment_count": 35,
      "start_date": "2024-03-01",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-10-16T04:56:58.652Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05871008"
    },
    {
      "nct_id": "NCT07092566",
      "title": "R.E.C.K vs Exparel in Robotic Nephrectomy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Carcinoma",
        "Nephrectomy / Methods",
        "Pain Management"
      ],
      "interventions": [
        {
          "name": "Ropivacaine HCL",
          "type": "DRUG"
        },
        {
          "name": "Exparel",
          "type": "DRUG"
        },
        {
          "name": "Epinephrine",
          "type": "DRUG"
        },
        {
          "name": "Clonidine HCL",
          "type": "DRUG"
        },
        {
          "name": "Ketorolac",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2025-11-14",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-13",
      "last_synced_at": "2026-10-16T04:56:58.652Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07092566"
    },
    {
      "nct_id": "NCT03867045",
      "title": "Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metastatic Renal Cell Carcinoma Treated With Cabozantinib"
      ],
      "interventions": [
        {
          "name": "Usability of an electronic symptom management application",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2019-08-21",
      "completion_date": "2019-12-16",
      "has_results": false,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-10-16T04:56:58.652Z",
      "location_count": 2,
      "location_summary": "Durham, North Carolina • Raleigh, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03867045"
    },
    {
      "nct_id": "NCT02605083",
      "title": "A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "eFT508",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Effector Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2015-12-03",
      "completion_date": "2019-03-22",
      "has_results": false,
      "last_update_posted_date": "2020-11-02",
      "last_synced_at": "2026-10-16T04:56:58.652Z",
      "location_count": 4,
      "location_summary": "Denver, Colorado • Sarasota, Florida • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02605083"
    },
    {
      "nct_id": "NCT01740154",
      "title": "Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fatigue",
        "Recurrent Renal Cell Cancer",
        "Stage IV Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "transcranial magnetic stimulation",
          "type": "PROCEDURE"
        },
        {
          "name": "electromyography",
          "type": "PROCEDURE"
        },
        {
          "name": "survey administration",
          "type": "OTHER"
        },
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2012-09",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2018-12-06",
      "last_synced_at": "2026-10-16T04:56:58.652Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01740154"
    },
    {
      "nct_id": "NCT01582672",
      "title": "Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Renal Cell Carcinoma",
        "Renal Cell Carcinoma",
        "Metastatic Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Standard Treatment",
          "type": "DRUG"
        },
        {
          "name": "AGS-003",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Argos Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 462,
      "start_date": "2012-11",
      "completion_date": "2018-04",
      "has_results": false,
      "last_update_posted_date": "2018-06-14",
      "last_synced_at": "2026-10-16T04:56:58.652Z",
      "location_count": 88,
      "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 71 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01582672"
    },
    {
      "nct_id": "NCT06483139",
      "title": "Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Myeloma",
        "Light Chain Nephropathy",
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "Plasma exchange",
          "type": "PROCEDURE"
        },
        {
          "name": "Daratumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 549,
      "start_date": "2024-06-01",
      "completion_date": "2026-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-10-16T04:56:58.652Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06483139"
    }
  ]
}